No Data
[Brokerage Focus] Zhongtai International: The results of the US election have limited impact on most companies in the pharmaceutical industry.
Kingwu Financial News | China Tai International stated that the results of the USA general election have limited impact on most companies in the pharmaceutical industry. Currently, apart from the pharmaceutical R&D outsourcing services (CXO) sector in the pharmaceutical industry which may be affected by the USA bio bill, other sectors are not greatly affected by geopolitical influences because most companies' main sources of revenue are in China. Chinese pharmaceutical companies started to go global around 2019. According to the bank's understanding, only nine Chinese innovative drugs have been approved in the USA from 2019 to date. Additionally, US hospitals typically prefer local products when choosing medications. Therefore, the bank believes that Chinese pharmaceutical companies will still find it difficult to pose a threat to the US pharmaceutical industry in the short term. Currently, the situation looks favorable.
Lu Chongmao: The "1+" mechanism has approved a total of 5 new drug applications, with the cost of 2 drugs decreasing by nearly 30%.
Dr. Constance Chan, Director of Health, stated at the Legislative Council meeting today (8th) that since the new drug approval mechanism ("1+1" mechanism) took effect, the Department of Health has received inquiries from more than 80 pharmaceutical companies, totaling over 260, and has approved a total of 5 new drug applications. These include 2 treatments for metastatic colorectal cancer, 1 treatment for paroxysmal nocturnal hemoglobinuria, 2 treatments for patients with parathyroid cancer and a certain type of hypercalcemia in patients with primary hyperparathyroidism. Dr. Constance Chan revealed that two of the new drugs for the treatment of metastatic colorectal cancer have been included in the public hospital authority's list of specialty drugs. The public hospital authority has also successfully completed procurement discussions.
Hong Kong stocks have seen unusual movements, with CRO concept stocks generally under pressure. The emotions are influenced by the results of the USA election. Institutions point out that the probability of the Biosecurity Law being an independent law may
CRO concept stocks are generally under pressure. As of the time of publication, GenScript Biotech (01548) fell by 6.68% to HKD 10.9; Viva Biotech (01873) fell by 3.16% to HKD 0.92; Pharmaron (03759) fell by 2.64% to HKD 16.22.
[Special VIP] Gong Cheng: Latest analysis and investment strategy of Zhongsheng Pharmaceutical.
SINO BIOPHARMACEUTICAL LTD. stock code: 1177 pe: 25 times forecast pe: 19 times earnings per share: $0.14 market cap: $65 billion business category: Health care products group Chairman: Xie Qirun major shareholder: Xie Chengrun (21.6%) 5-year performance year: 2019/2020/2021/2022/2023 Revenue (RMB billion): 242/237/269/288/262 Gross profit (RMB billion): 193/185/215/230/2
Hong Kong stock concept tracking | The end of medical insurance negotiations is very encouraging for innovative drugs to be included in medical insurance at reasonable prices (with concept stocks)
The on-site negotiation and bidding stages for the adjustment of the national medical insurance pharmaceutical catalog in 2024 officially ended recently.
Mainland medical insurance pharmaceutical catalog adjustment negotiations are expected to end, and the new version of the catalog is expected to be released by the end of the month.
According to a report by the People's Daily, following the established work arrangements, from October 27th to 30th, under the organization of the National Medical Insurance Bureau, 25 negotiating experts from various provincial medical insurance departments conducted on-site negotiations and bidding with 127 enterprises, involving 162 types of pharmaceuticals, including 117 types of pharmaceuticals outside the medical insurance catalog and 45 types of pharmaceuticals within the negotiated renewal in the medical insurance catalog. This year's on-site negotiation work progressed smoothly and steadily, with overall results basically consistent with previous years, meeting expectations. The new version of the medical insurance pharmaceutical catalog after the “expansion” is expected to be released to the public at the end of November, and will be officially implemented starting next year. Relevant to the National Medical Insurance Administration's Pharmaceutical Service Management Department.
No Data
No Data